Rigel Pharmaceuticals | RIGL - Cash And Equivalent


Rigel Pharmaceuticals reported $48.53M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Celldex Therapeutics USD 47.45M 11.72M Jun/2026
Daiichi Sankyo JPY 449.81B 92.35B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 1.01B 891.62M Jun/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Veracyte USD 299.52M 36.38M Jun/2026